Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
May 08, 2026
TickeronGET DAILY SIGNALS
iShares U.S. Medical Devices ETF (IHI): Analyzing the -8.5% Drop Over the Past 30 Days

iShares U.S. Medical Devices ETF (IHI): Analyzing the -8.5% Drop Over the Past 30 Days

Key Takeaways

  • IHI declined approximately -8.5% over the past 30 days amid softer demand for medical devices and broader healthcare sector pressures.
  • Over the past quarter, the ETF fell around -15%, underperforming the broader health category due to valuation adjustments and muted procedural volumes.
  • Top holdings like ISRG and EW contributed significantly to the downside, while gains in ABT and SYK provided limited offset.
  • Higher interest rates and sector rotation away from growth-oriented healthcare stocks weighed on performance.
  • Fund flows showed net outflows over the past year, reflecting reduced investor interest in the niche medical devices theme.

Understanding IHI and Its Portfolio Focus

The iShares U.S. Medical Devices ETF (IHI) tracks the Dow Jones U.S. Select Medical Equipment Index, offering targeted exposure to U.S. companies that manufacture and distribute medical devices, including imaging equipment, prosthetics, and surgical tools. It holds about 52 stocks, with the top 10 making up over 75% of assets. Key positions include ISRG (Intuitive Surgical, ~16.5%), ABT (Abbott Laboratories, ~16%), and SYK (Stryker, ~11%). The portfolio is entirely allocated to healthcare, zeroing in on the medical devices subsector. This focus makes IHI particularly sensitive to industry challenges like reduced hospital spending and procedural delays, which has amplified its recent declines relative to more diversified healthcare ETFs.

IHI's Recent Price Action: 30 Days and Quarterly View

In the last 30 days, IHI fell from around $54.35 to $49.77, marking a -8.5% decline. The path was volatile and downward-trending, with sharp drops in late April speeding up the selloff. Over the past quarter, the retreat was even steeper at -15% from near $58.50 levels, driven by steady erosion amid broader market shifts. These moves line up with trailing returns of -4.3% for the prior month and -14.9% for three months as of early May, pointing to a bearish, range-bound pattern with lower highs. From what I see, this confirms ongoing pressure in the space.

Key Drivers Behind IHI's 30-Day Decline

The ETF's downturn over the past 30 days came mainly from weakness in its largest holdings and sector headwinds. Top holding ISRG dropped over 2%, pulling IHI lower given its 16.5% weight, while EW (Edwards Lifesciences) slid on concerns about cardiac device demand. Gains in ABT (up significantly) and SYK offered some cushion, but the portfolio's concentration magnified the losses. Softer demand for implants and neurotechnology—evident in Stryker's Q1 earnings miss—added to the strain. On the macro side, high interest rates raised financing costs for growth-reliant medtech companies, spurring profit-taking. Net fund outflows and a shift in sentiment toward value sectors only intensified the pressure. I also checked this using Tickeron’s AI Screener to gauge how IHI stacks up against peers.

Factors Shaping IHI's Quarterly Performance

The -15% quarterly slide built from mounting pressures on medical devices, including stretched valuations after 2025 gains and tighter macro conditions. Holdings like ISRG and EW lagged due to slower procedural growth and supply chain hurdles, while higher rates discounted future cash flows for innovation-focused firms. Earnings from peers like Stryker showed weaker demand in orthopedics and surgery, diverging from broader healthcare strength. Institutional outflows reached hundreds of millions over the year, with assets under management shrinking from $3.5B+ peaks, signaling fading confidence. Longer-term issues like hospital budget limits and rotation to cyclicals deepened the underperformance against health benchmarks. One thing that stands out is how these dynamics have persisted.

Why I Rely on Tickeron’s AI Screener for ETF Analysis

In my research, I often turn to Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs through filters on technical patterns, fundamentals, trends, volatility, and AI signals. It scans thousands of assets using criteria like industry, market cap, indicators, price patterns, and performance metrics, surfacing trade ideas, breakouts, and opportunities faster than manual methods. This has been invaluable for tracking sector performance and dynamic ETF moves like those in medical devices. I’m watching it closely for the next insights.

Looking Ahead for IHI: Key Factors to Monitor

Looking forward, keep an eye on demand signals in medical devices, such as hospital procedure volumes and Q2 earnings from leaders like SYK and ISRG. The macro backdrop—Federal Reserve rate decisions and inflation—will shape valuations for growth names. Major holdings' progress in areas like robotic surgery adoption matters too. Supply chain stability and regulatory shifts could also influence the ETF. Risks persist from extended weak demand or outflows, but improved flows or rate cuts might aid a rebound. This is important because it frames the potential path.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: IHI

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


IHI's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for IHI turned positive on October 08, 2026. Looking at past instances where IHI's MACD turned positive, the stock continued to rise in 47 of 53 cases over the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on IHI as a result. In 72 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

IHI moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IHI crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.

The 50-day moving average for IHI moved above the 200-day moving average on November 10, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +2.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where IHI advanced for three days, in 234 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

The Aroon Indicator entered an Uptrend today. In 238 of 292 cases where IHI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.

Bearish Trend Analysis

The 10-day RSI Indicator for IHI moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 56 of 70 cases where IHI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IHI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

IHI broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Intuitive Surgical (NASDAQ:ISRG), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The investment seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index, which measures the performance of the medical equipment sector of the U.S. equity market, as defined by S&P Dow Jones Indices LLC. The index includes medical equipment companies, including manufacturers and distributors of medical devices such as magnetic resonance imaging scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

Market Cap

The average market capitalization across the iShares U.S. Medical Devices ETF (IHI) ETF is 21.89B. The market cap for tickers in the group ranges from 320.57M to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is OFIX at 320.57M.

High and low price notable news

The average weekly price growth across all stocks in the iShares U.S. Medical Devices ETF (IHI) ETF was 27%. For the same ETF, the average monthly price growth was 61%, and the average quarterly price growth was 113%. TMDX experienced the highest price growth at 33%, while IRTC experienced the biggest fall at -28%.

Volume

The average weekly volume growth across all stocks in the iShares U.S. Medical Devices ETF (IHI) ETF was -45%. For the same stocks of the ETF, the average monthly volume growth was -20% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 62
P/E Growth Rating: 53
Price Growth Rating: 45
SMR Rating: 77
Profit Risk Rating: 88
Seasonality Score: 36 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
AMD fell -5.03% to $555.85 in regular-session trading Friday, down -$29.45 from Thursday's close of $585.30, as of 9:42 a.m. ET shortly after the opening bell. No verified company-specific news or fundamental catalyst found: the decline tracks a broad semiconductor pullback and is consistent with profit-taking after a +44.7% rebound from the Nov. 5 close of $404.40, with the stock's typical daily swing running at 3.6%.
BZ dropped sharply, sliding from a $16.72 prior close to $13.48 (-19.38%), with the decline beginning in premarket and deepening into the early regular session. No verified company-specific news or fundamental catalyst was issued; the fall tracked a broad China ADR selloff (the Nasdaq Golden Dragon index slid more than 2%), but that alone is too small to explain a ~20% drop — the stock's Hong Kong listing fell only -2.6%.
NBIS fell from $154.69 to $129.12, down -16.53%, with the decline starting in premarket trading and continuing through the regular session. The drop followed Q3 results: revenue of $980.8M (+571% YoY) beat estimates, but management cut 2026 revenue guidance to the low end of its range on third-party capacity delays and raised 2026 capex to roughly $27B, reviving financing and execution fears.
The $1 target in this article is not an analyst price target; it is the $1.00 Nasdaq minimum bid price requirement, the level Cenntro itself has publicly targeted through a 1-for-60 reverse stock split. Cenntro trades near $0.12 per share, meaning reaching $1 would require an increase of roughly 730%—an exceptionally large move.
The central target of $21 is the arithmetic mean of three recently attributable analyst price targets on RUM — $25 (Lake Street), $15 (Texas Capital), and $22 (Maxim Group) — which average roughly $20.67. With shares trading near $5.90 after a post-earnings surge, reaching $21 would require a gain of roughly 256%, a very large move.
iShares U.S. Medical Devices ETF (IHI): Analyzing the -8.5% Drop Over the Past 30 Days